ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $483,744 | -37.0% | 3,200 | -47.5% | 0.00% | -50.0% |
| Q4 2023 | $768,295 | +134.4% | 6,100 | +74.3% | 0.00% | – |
| Q3 2023 | $327,740 | -8.2% | 3,500 | -12.5% | 0.00% | -100.0% |
| Q2 2023 | $357,000 | -84.7% | 4,000 | -81.7% | 0.00% | -80.0% |
| Q1 2023 | $2,337,396 | +18.9% | 21,800 | +35.4% | 0.01% | -16.7% |
| Q4 2022 | $1,966,293 | +495.8% | 16,100 | +403.1% | 0.01% | +500.0% |
| Q3 2022 | $330,000 | -9.1% | 3,200 | -17.9% | 0.00% | 0.0% |
| Q2 2022 | $363,000 | -74.2% | 3,900 | -67.5% | 0.00% | -80.0% |
| Q1 2022 | $1,408,000 | +110.5% | 12,000 | +185.7% | 0.01% | +66.7% |
| Q3 2021 | $669,000 | +58.9% | 4,200 | +31.2% | 0.00% | +50.0% |
| Q2 2021 | $421,000 | -16.3% | 3,200 | -17.9% | 0.00% | 0.0% |
| Q1 2021 | $503,000 | +11.8% | 3,900 | +44.4% | 0.00% | 0.0% |
| Q4 2020 | $450,000 | – | 2,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |